Psoriasis Clinical Trial
A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Palmoplantar Pustulosis
Summary
A study to evaluate the efficacy and safety, and pharmacokinetic (PK) profile of multiple doses of imsidolimab (ANB019) in adults with palmoplantar pustulosis (PPP)
Eligibility Criteria
Inclusion Criteria:
Clinically confirmed diagnosis of PPP
Disease duration of at least 6 months prior to screening
Present with active pustules on palms or/and soles at screening
Exclusion Criteria:
Any other ongoing inflammatory disease that interfere with the investigator's ability to evaluate the subject's response to therapy
History of recurrent or active/serious infection
Ongoing use of psoriasis prohibited medication
Other protocol-defined inclusion/exclusion criteria may apply
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 34 Locations for this study
Birmingham Alabama, 35233, United States
Phoenix Arizona, 85032, United States
Encino California, 91436, United States
Santa Monica California, 90405, United States
Fort Lauderdale Florida, 33316, United States
Miami Florida, 33155, United States
Pembroke Pines Florida, 33028, United States
Tampa Florida, 33607, United States
Indianapolis Indiana, 46250, United States
Plainfield Indiana, 46168, United States
Overland Park Kansas, 66215, United States
Ann Arbor Michigan, 48109, United States
Saint Louis Missouri, 63110, United States
Saint Louis Missouri, 63117, United States
Wilmington North Carolina, 28405, United States
Columbus Ohio, 43230, United States
Norman Oklahoma, 73071, United States
Portland Oregon, 97239, United States
Portland Oregon, 97239, United States
Dallas Texas, 75230, United States
Surrey British Columbia, , Canada
Markham Ontario, , Canada
Sudbury Ontario, , Canada
Drummondville Quebec, , Canada
Montréal Quebec, , Canada
Montréal Quebec, , Canada
Bad Bentheim , 48455, Germany
Berlin , 10117, Germany
Berlin , 10789, Germany
Bonn , 53127, Germany
Hamburg , 20253, Germany
Hamburg , 22391, Germany
Schwerin , 19055, Germany
Gdańsk , 80-54, Poland
Katowice , 40-61, Poland
Olsztyn , 10-22, Poland
Ostrowiec Świętokrzyski , 27-40, Poland
Rzeszów , 35-05, Poland
Szczecin , 70-33, Poland
Wrocław , 50-56, Poland
Åódź , 90-26, Poland
How clear is this clinincal trial information?

Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.